The effect of etofibrate retard, bezafibrate and procetofen.
The effects and side effects of 500 mg of etofibrate retard were comared with those of 100 mg t.i.d. of procetofene and of 200 mg t.i.d. of bezafibrate in two different studies in 60 and 63 outpatients respectively. In types IIa, IIb and IV hyperlipoproteinaemia cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were affected markedly stronger by procetofene and bezafibrate than by etofibrate retard. This impact was not only superior in its quantity by also in its proportion of responding patients. Side effects were a flush under etofibrate retard and gastric discomfort, headache and nausea in about 5% under all three drugs. Etofibrate retard did not give significant changes in the laboratory parameters while procetofene and bezafibrate slightly increased transaminases and creatinine. Alcaline phosphatase and GT were significantly lowered. Uric acid decreased under procetofene and increased under bezafibrate.
D000368:Aged; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011422:Propionates / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D011422:Propionates; D014280:Triglycerides; C009746:etofibrate; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate; D011345:Fenofibrate; D001629:Bezafibrate